Physician profile
Gregory A Brian
NPI 1184616252
$15,099.65
in general payments reported to CMS, 2019-2025
50 companies · $2,476 in 2025
The $2,476 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,037 · 2020: $2,013 · 2021: $1,974 · 2022: $1,588 · 2023: $2,198 · 2024: $2,813 · 2025: $2,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,488.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,235.73 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,701.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,435.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,098.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,031.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $789.71 | 2019-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $616.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $552.65 | 2020-2025 | Rexulti, Nuedexta |
| Allergan, INC. | $550.03 | 2019-2020 | |
| Amgen INC. | $542.16 | 2019-2025 | Otezla, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $459.47 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $410.56 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $377.35 | 2019-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $323.60 | 2020-2025 | Nexletol |
| Abbott Laboratories | $274.76 | 2021-2025 | Freestyle Libre 3 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Brian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.